Volume : 09, Issue : 09, September – 2022
Title:
39.CLINICAL CHARACTERISTICS AND SURVIVAL RATES OF HEPATOCELLULAR CARCINOMA, A SYSTEMATIC REVIEW
Authors :
Bassam Farhan Alakhras , Zahra Mohammed almusa , Sarah Mohammed Alqahtani , zahra ali alqambar , Amal Ahmad Alorabi , fatimah ali alqambar , Almaha Yousef Alabbad , Zainab Ali alQambar
Abstract :
Background: Hepatocellular carcinoma (HCC), which accounts for approximately 75% of primary liver tumors, is one of the most serious complications of chronic liver disease. It is now the sixth most common cancer in the world, contributing to the third leading cause of death from cancer.
Objectives: The study aims to summarize current evidences regarding clinical characteristics and survival rates of hepatocellular carcinoma
Methods: For article selection, the PubMed database were used. All relevant articles relevant with our topic and other articles were used in our review. Other articles that were not related to this field were excluded. The data was extracted in a specific format that was reviewed by the group members.
Conclusion: In conclusion, 13 were enrolled for final data extraction. The most common cause of HCC among Medicare patients is NAFLD which was linked to less HCC surveillance reception, early-stage identification, and somewhat worse survival when compared to other etiologies. Viremic HCC patients had lower survival than post-SVR patients and viremic patients who were treated and achieved SVR after HCC diagnosis.
Key words: liver, carcinoma, tumor, HCC, hepatocellular carcinom
Cite This Article:
Please cite this article in Bassam Farhan Alakhras et al, Clinical Characteristics And Survival Rates Of Hepatocellular Carcinoma, A Systematic Review., Indo Am. J. P. Sci, 2022; 09(09).
Number of Downloads : 10
References:
1. Singal, Amit G et al. “Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.” PLoS medicine vol. 11,4 e1001624. 1 Apr. 2014, doi:10.1371/journal.pmed.1001624
2. Waller, Lisa P et al. “Hepatocellular carcinoma: A comprehensive review.” World journal of hepatology vol. 7,26 (2015): 2648-63. doi:10.4254/wjh.v7.i26.2648
3. Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol. 2014;20:12945–12955.
4. Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M, et al. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int. 2014;2014:203693.
5. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844–855
6. Sun HC, Zhang W, Qin LX, Zhang BH, Ye QH, Wang L, Ren N, Zhuang PY, Zhu XD, Fan J, Tang ZY. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol. 2007 Nov;47(5):684-90.
7. Kubo S, Hirohashi K, Yamazaki O, Matsuyama M, Tanaka H, Horii K, Shuto T, Yamamoto T, Kawai S, Wakasa K, Nishiguchi S, Kinoshita H. Effect of the presence of hepatitis B e antigen on prognosis after liver resection for hepatocellular carcinoma in patients with chronic hepatitis B. World J Surg. 2002 May;26(5):555-60.
8. Kim BK, Park JY, Kim DY, Kim JK, Kim KS, Choi JS, Moon BS, Han KH, Chon CY, Moon YM, Ahn SH. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int. 2008 Mar;28(3):393-401.
9. Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, Huo TI, Sheen IJ, Lee SD, Lui WY. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009 Nov;51(5):890-7.
10. Wang YG, Wang P, Wang B, Fu ZJ, Zhao WJ, Yan SL. Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2014;9(5):e95485.
11. Bruix J, Sherman M (2010) Management of hepatocellular carcinoma: an update. Hepatology 53: 1–35
12. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421–430.
13. Ding J, Wen Z. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. BMC Cancer. 2021 Oct 29;21(1):1157. doi: 10.1186/s12885-021-08904-3. PMID: 34715816; PMCID: PMC8555190.
14. Chen JG, Zhu J, Zhang YH, Chen YS, Ding LL, Chen HZ, Shen AG, Wang GR. Liver Cancer Survival: A Real World Observation of 45 Years with 32,556 Cases. J Hepatocell Carcinoma. 2021 Aug 31;8:1023-1034. doi: 10.2147/JHC.S321346. PMID: 34513745; PMCID: PMC8418373.
15. Tang Y, Wang L, Teng F, Zhang T, Zhao Y, Chen Z. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis. Int J Med Sci. 2021 Jan 1;18(1):187-198. doi: 10.7150/ijms.50883. PMID: 33390787; PMCID: PMC7738961.
16. Straś W, Gotlib J, Małkowski P, Wasiak D, Śliwczyński A, Panczyk M, Tronina O, Brzozowska M. Overall Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Polish Experience. Med Sci Monit. 2021 Aug 31;27:e931856. doi: 10.12659/MSM.931856. PMID: 34462415; PMCID: PMC8418957.
17. Pelizzaro F, Vitale A, Sartori A, Vieno A, Penzo B, Russo FP, Frigo AC, Giannini EG, Piccinnu M, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Celsa C, Marra F, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Coccoli P, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F, Farinati F, On Behalf Of Ita Li Ca Study Group. Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. Cancers (Basel). 2021 Feb 20;13(4):897. doi: 10.3390/cancers13040897. PMID: 33672751; PMCID: PMC7924561.
18. Ratana-Amornpin S, Vilaichone RK, Miftahussurur M, Aumpan N, Kaewkarnjanarat K, Nun-Anan P, Chonprasertsuk S, Siramolpiwat S, Bhanthumkomol P, Pornthisarn B, Uchida T, Mahachai V. Clinical Features and Overall Survival of Females with Hepatocellular Carcinoma: A Retrospective Study and Review of the Literature in the Association of Southeast Asian Nations. Int J Womens Health. 2021 Jul 22;13:717-725. doi: 10.2147/IJWH.S311419. PMID: 34326670; PMCID: PMC8314927.
19. Toyoda H, Hiraoka A, Uojima H, Nozaki A, Shimada N, Takaguchi K, Abe H, Atsukawa M, Matsuura K, Ishikawa T, Mikami S, Watanabe T, Itobayashi E, Tsuji K, Arai T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Okubo T, Ehira T, Kumada T, Tanaka J. Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response. Hepatol Commun. 2021 May 5;5(7):1290-1299. doi: 10.1002/hep4.1716. PMID: 34278176; PMCID: PMC8279467.
20. Wang J, Li Z, Liao Y, Li J, Dong H, Peng H, Xu W, Fan Z, Gao F, Liu C, Liu D, Zhang Y. Prediction of Survival and Analysis of Prognostic Factors for Patients With Combined Hepatocellular Carcinoma and Cholangiocarcinoma: A Population-Based Study. Front Oncol. 2021 Jul 16;11:686972. doi: 10.3389/fonc.2021.686972. PMID: 34336671; PMCID: PMC8322675.
21. Kim YA, Kang D, Moon H, Sinn D, Kang M, Woo SM, Chang YJ, Park B, Kong SY, Guallar E, Shin SY, Gwak G, Back JH, Lee ES, Cho J. Survival in untreated hepatocellular carcinoma: A national cohort study. PLoS One. 2021 Feb 4;16(2):e0246143. doi: 10.1371/journal.pone.0246143. PMID: 33539397; PMCID: PMC7861368.
22. Karim MA, Singal AG, Kum HC, Lee YT, Park S, Rich NE, Noureddin M, Yang JD. Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol. 2022 Mar 17:S1542-3565(22)00284-1. doi: 10.1016/j.cgh.2022.03.010. Epub ahead of print. PMID: 35307595; PMCID: PMC9481743.
23. Cho YY, Yu SJ, Lee HW, Kim DY, Kang W, Paik YH, Sung PS, Bae SH, Park SC, Doh YS, Kim KM, Jang ES, Kim IH, Kim W, Kim YJ. Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study. J Hepatocell Carcinoma. 2021 Jun 18;8:613-623. doi: 10.2147/JHC.S304439. PMID: 34169044; PMCID: PMC8219232.
24. Yeh ML, Liang PC, Tsai PC, Wang SC, Leong J, Ogawa E, Jun DW, Tseng CH, Landis C, Tanaka Y, Huang CF, Hayashi J, Hsu YC, Huang JF, Dai CY, Chuang WL, Nguyen MH, Yu ML. Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR. Cancers (Basel). 2021 Jul 9;13(14):3455. doi: 10.3390/cancers13143455. PMID: 34298669; PMCID: PMC8306695.
25. Li B, Liu A, Wen Y, Yang G, Zhao J, Li X, Mao Y, Li B. The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data. J Clin Lab Anal. 2021 Sep;35(9):e23932. doi: 10.1002/jcla.23932. Epub 2021 Aug 17. PMID: 34403527; PMCID: PMC8418514.
26. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. development, growth, and spread: key pathologic and imaging aspects. Radiology. 2014;272(3):635–654. doi: 10.1148/radiol.14132361
27. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, staging, and Management of Hepatocellular Carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. doi: 10.1002/hep.29913.
28. Rovesti G, Orsi G, Kalliopi A, et al. Impact of baseline characteristics on the overall survival of HCC patients treated with sorafenib: Ten years of experience. Gastrointest Tumors. 2019;6(3–4):92–107.
29. Liu L, Zhang Q, Geng J, et al. Comparison of radiofrequency ablation combined with sorafenib or sorafenib alone in patients with ECOG performance score 1: Identifying optimal candidates. Ann Transl Med. 2020;8(9):583.
30. Kaneko S, Ikeda K, Matsuzaki Y, et al. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: Interim analysis of a prospective postmarketing all-patient surveillance study. J Gastroenterol. 2016;51(10):1011–21.
31. Kudo M, Ikeda M, Takayama T, et al. Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: A subgroup analysis of GIDEON. J Gastroenterol. 2016;51(12):1150–60.
32. Ye S-L, Chen X, Yang J, et al. Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: Final outcome from the Chinese patient subset of the GIDEON study. Oncotarget. 2016;7(6):6639–48.
33. Raoul J-L, Bruix J, Greten TF, et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol. 2012;56(5):1080–88.
34. King J, Palmer DH, Johnson P, et al. Sorafenib for the treatment of advanced hepatocellular cancer – a UK audit. Clin Oncol (R Coll Radiol) 2017;29(4):256–62.
35. Wörns MA, Koch S, Niederle IM, et al. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. Dig Liver Dis. 2013;45(5):408–13.
36. Tan D, Yopp A, Beg MS, Gopal P, Singal AG. Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther. 2013; 38:703–12. 10.1111/apt.12450
37. Denton M, Prus S, Walters V. Gender differences in health: a Canadian study of the psychosocial, structural and behavioural determinants of health. Soc Sci Med. 2004; 58:2585–600.